RFC
ELOS

Russell Frank Company’s Syneron Medical Ltd ELOS Stock Holding History

Russell Frank Company’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-54,789
Closed -$682K – 2914
2014
Q1 		$682K Buy
54,789
+6,065
+12% +$71.8K ﹤0.01% 2252
2013
Q4 		$597K Buy
+48,724
New +$506K ﹤0.01% 2273

Other funds holding ELOS

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $480M AUM 32.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Russell Frank Company's ELOS Position: Q2 2014 in Review

Russell Frank Company sold out of Syneron Medical Ltd (ELOS) in Q2 2014, closing a stake of 54,789 shares — an estimated $682K sold.

Russell Frank Company first reported a position in ELOS in Q4 2013 and held it in 2 quarters. The position peaked at $682K in Q1 2014. 61 funds tracked by Wall St. Rank hold ELOS as of Q2 2014.

  • Russell Frank Company reported no remaining Syneron Medical Ltd position as of Q2 2014 after selling out during the quarter.
  • Russell Frank Company sold 54,789 Syneron Medical Ltd shares in Q2 2014, an estimated $682K.
  • Russell Frank Company first reported a position in Syneron Medical Ltd in Q4 2013 and held it in 2 quarters.
  • Russell Frank Company's Syneron Medical Ltd position peaked at $682K in Q1 2014.
  • 61 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2014.

Based on Russell Frank Company's 13F filing for Q2 2014, filed 14 Aug 2014.